Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

PURPOSE: Daratumumab (DARA) is a humanized anti-CD38 monoclonal antibody and approved as monotherapy or in combination with standard of care regimens for the treatment of multiple myeloma (MM). DARA intravenous (IV) administration is time-consuming; availability of DARA subcutaneous (SC) is expected...

Descripción completa

Detalles Bibliográficos
Autores principales: Slavcev, Mary, Spinelli, Allison, Absalon, Elisabeth, Masterson, Tara, Heuck, Christoph, Lam, Annette, De Cock, Erwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197571/
https://www.ncbi.nlm.nih.gov/pubmed/34135605
http://dx.doi.org/10.2147/CEOR.S302682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197571/
https://www.ncbi.nlm.nih.gov/pubmed/34135605
http://dx.doi.org/10.2147/CEOR.S302682

Ejemplares similares